Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Pierpaolo CorrealeRita Emilena SaladinoDiana GiannarelliRocco GiannicolaRita AgostinoNicoletta StaropoliAlessandra StrangioTeresa Del GiudiceValerio NardoneMaria AltomontePierpaolo PastinaPaolo TiniAntonia Consuelo FalzeaNatale ImbesiValentina ArcatiGiuseppa RomeoDaniele CaraccioloAmalia LuceMichele CaragliaAntonio GiordanoLuigi PirtoliAlois NecasEvzen AmlerVito BarbieriPierfrancesco TassonePierosandro TagliaferriPublished in: Journal for immunotherapy of cancer (2021)
This study demonstrate that class I and II HLA allele characterization to define tumor immunogenicity has relevant implications in predicting nivolumab efficacy in mNSCLC and provide the rationale for further prospective trials of cancer immunotherapy.